Drug
Mk2461
Mk2461: highest development phase Phase 1/2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK2461 NCT00496353 | Phase 1/2 | Neoplasm |
Latest
No recent events.
Follow Mk2461 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.